Biocon Q3 preview: Firm likely to post profit of Rs 192 crore against a loss in Q3 FY23
EBITDA, or earnings before interest, taxes, depreciation, and amortisation, is also set to log a double-digit increase of 29 per cent in Q3 to Rs 830 crore as against Rs 646 crore logged in Q3 FY23.
Moreover, there is a view that the weak results of Syngene, which is the company's global innovation-focused subsidiary, may weigh on the firm.